Nice approves second-line drug for rheumatoid arthritis
Golimumab can be used as a second-line option in combination with methotrexate to treat rheumatoid arthritis, Nice has ruled.
The TNF inhibitor is recommended only for patients who have responded inadequately to disease-modifying antirheumatic drugs (DMARDs) alone, the advisory body has said.
However, it should only be considered if the manufacturer provides the 100mg dose at the same cost as the 50mg dose, Nice added.